ACC 2019 | The New ACC/AHA Guidelines on Primary Prevention Focus on Life Style, Diet and Socioeconomic Factors.

These guidelines basically remind us that we should focus on life style changes to best prevent heart disease, heart failure and atrial fibrillation. These changes, of course, should be permanent.

ACC 2019 | Las nuevas guías de prevención primaria ACC/AHA con foco en estilo de vida, dieta y factores socioeconómicos.It is estimated that life style changes translate into 80% risk reduction of heart disease.

 

These recommendations are based on 9 topics: risk estimation, diet, physical activity, obesity, diabetes, cholesterol, hypertension, giving up smoking and the use of aspirin.

 

Social factors have been one of the most difficult fronts and the one with most impact. Physicians seldom show concern about whether patients can afford the drugs we prescribe, or whether they will be able to follow a healthy diet.


Read also: ACC 2019 | SAFARI: Unexpectedly, Radial Approach Offers No Benefits In STEMI.


Moreover, we should routinely try to detect psychosocial stressors and support our patients with savvy advice.

 

For adults between 40 and 75, we recommend screening for traditional risk factors and estimating cardiovascular risk at 10 years (recommendation class I).

 

For patients between 20 and 39, it is reasonable to assess risk factors every 4 to 6 years (recommendation class IIa).


Read also: ACC 2019 | POET: Oral Antibiotics with Good Long-Term Results for Endocarditis.


Patients presenting intermediate or border risk could be better stratified with other markers such as family history, metabolic syndrome, chronic kidney disease, or C-reactive protein.

 

Guidelines also suggest consuming more vegetables, fruits, legumes, whole grains and fish, as well as warning against the consumption of salt, fired foods, processed meats and sugary drinks.

 

They recommend 150 minutes of moderate activity (walking, swimming, cycling) or 75 minutes of a more vigorous activity, and if neither were possible, at least 10 minutes can make a significant difference.


Read also: ACC 2019 | Having an Infarction at Very Young Age or 10 Years Later Does Not Change Long-Term Mortality.


As regards aspirin, it is not recommended as primary prevention in >70-year individuals, or with increased bleeding risk (recommendation class III). For individuals between 40 and 70, aspirin can be considered if there is high cardiovascular risk or low bleeding risk (recommendation class IIb). For most patients, aspirin is not indicated as primary prevention.

 

Original title: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease.

Reference: Arnett DK et al. Circulation 2019; Epub ahead of print.

 

Guias-de-prevención-primaria


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...